White Paper: The Sequential Parallel Comparison Design for Reducing Placebo Response

Published on:
March 8, 2022

About Sequential Parallel Comparison Design

In the past several decades, it is recognized that increasing spending of clinical research does not reflect an increase of the success rate of drug development. Moreover, the pharmaceutical industry has realized that the classical structured clinical trials do not offer enough flexibility to make use of continuously emerging knowledge that is generated as trial progresses.

One of the innovations strongly recommended by the authorities is the use of adaptive designs in clinical trials and the potential use of Bayesian approach in clinical research. Although planning such trials comes at the cost of additional operational complexity, adaptive designs offer the benefit of flexibility to update trial design and objectives as data accrue.

In this white paper, we will explore a two-stage adaptive design called the “Sequential Parallel Comparison Design” (SPCD) for enrichment of placebo non-responders.

Related news

Events November 4, 2022
We are pleased to announce that we will be joining as sponsors and delegates PHUSE EU, an event that brings together the PHUSE global community to collaborate on hot topics guiding(...)
Biometrics Biostatistics
Publications September 16, 2022
Considerations for Analyzing and Interpreting Data from Biometric Monitoring Technologies in Clinical Trials
The rise of technology in clinical research allows us to capture meaningful aspects of health in clinical study participants.
Biometrics Clinical eCOA
Events May 27, 2022
PSI 2022 Conference
We are pleased to announce that this year we will be joining PSI 2022 Conference, the principal annual event for statisticians in the pharmaceutical industry, as sponsors, exhibitors, and delegates.
Events May 19, 2022
DIA 2022 Global Annual Meeting
We are pleased to announce that we will be joining DIA 2022 Global Annual Meeting as exhibitors and delegates.
Biometrics Clinical Life Sciences Regulatory
Publications March 22, 2022
Biometrics: Industry State of Affairs
We spoke with Katell Bernois, Director of Statistical Consulting at Alira Health, to understand the key trends that are changing the biometrics industry.
Publications March 11, 2022
Addressing Common CDISC Compliance Findings for Regulatory Submission
Learn from the team of industry CDISC experts how to explain common SDTM/ADAM issues to regulatory reviewers.
Publications March 8, 2022
Case Study: Effective Early Phase Oncology Study Design
Discover more about how to use Bayesian Optimal Interval Design to effectively design an Early Phase Oncology study.
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.